Lilly’s Ramucirumab Makes An Impact In Tough-To-Treat Gastric Cancer, But Will It Be Enough?
Executive Summary
The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.
You may also be interested in...
Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.
Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.
Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.